Compositions and Uses Thereof
AssigneePurposeful IKE
InventorsGeorgios Drakakis, Charalampos Chomenidis, Georgia Tsiliki
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions for use in the treatment, management or amelioration of FMR1 mediated autism and Fragile X Syndrome (FXS), wherein the composition comprises one or more tryptophans or derivatives thereof. The invention also relates to one or more tryptophans or derivatives thereof and one or more ergot alkaloids, derivatives or mimetics thereof for use as medicaments for treating a range of autistic diseases and diseases having an autistic component.
Claims29
A method of treating or managing of FMR1 mediated autism comprising, administering a therapeutically effective amount of a medicament to an individual being in need of treating or managing FMR1 mediated autism, wherein the medicament comprises one or more of the following:
- 5-hydroxytryptophan (5-HTP) (oxitriptan), L-tryptophan, D-tryptophan, 2-hydroxytryptophan;
- imino-tryptophan;
- indoximod, 1-hydroperoxy-L-tryptophan, tryptophanamide, 5-fluorotryptophan, 7-aza-L-tryptophan;
- and oglufanide.
(canceled)
A method of treating or managing Fragile X Syndrome (FXS) comprising, administering a therapeutically effective amount of a medicament to an individual being in need of treating or managing Fragile X Syndrome (FXS), wherein the medicament comprises one or more of the following:
- 5-hydroxytryptophan (5-HTP) (oxitriptan), L-tryptophan, D-tryptophan, 2-hydroxytryptophan;
- imino-tryptophan;
- indoximod, 1-hydroperoxy-L-tryptophan, tryptophanamide, 5-fluorotryptophan, 7-aza-L-tryptophan;
- and oglufanide.
(canceled)
A method of treating or managing FMR1 mediated autism comprising, administering a therapeutically effective amount of a medicament to an individual being in need of treating or managing FMR1 mediated autism, wherein the medicament comprises:
- one or more of the of the following:
- 5-hydroxytryptophan (5-HTP) (oxitriptan), L-tryptophan, D-tryptophan, 2-hydroxy-tryptophan;
- imino-tryptophan;
- indoximod, 1-hydroperoxy-L-tryptophan, tryptophanamide, 5-fluorotryptophan, 7-aza-L-tryptophan, and oglufanide;
- and
- one or more of the of the following:
- ergoloid mesylates, methysergide, dihydroergotamine, lisuride ergotamine nicergoline, dihydroergocristine, dihydroergocornine, dihydroergocryptine, ergometrine, methylergometrine, cabergoline, pergolide, bromocriptine, lysergic acid diethylamide, terguride, and metergoline.
(canceled)
(canceled)
(canceled)
A method of treating or managing an autism disease or a disease where autism is a known component comprising, administering a therapeutically effective amount of a medicament to an individual being in need of treating or managing an autism disease or a disease where autism is a known component;
- wherein the medicament comprises:
- a first set of one or more ingredients, wherein the one or more ingredients are selected from:
- 5-hydroxytryptophan (5-HTP) (oxitriptan), L-tryptophan, D-tryptophan, 2-hydroxy-tryptophan;
- imino-tryptophan;
- indoximod, 1-hydroperoxy-L-tryptophan, tryptophanamide, 5-fluorotryptophan, 7-aza-L-tryptophan;
- and oglufanide;
- and
- a second set of one or more ingredients, wherein the one or more ingredients are selected from:
- ergoloid mesylates, methysergide, dihydroergotamine, lisuride ergotamine nicergoline, dihydroergocristine, dihydroergocornine, dihydroergocryptine, ergometrine, methylergometrine, cabergoline, pergolide, bromocriptine, lysergic acid diethylamide, terguride, and metergoline.
(canceled)
-25. (canceled)
Dependencies are inferred from the claim text.